Corporate Profile for MGI PHARMA, Inc., dated Feb. 8, 2002.Business Editors --(BUSINESS WIRE) The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: Feb. 8, 2002
Company Name: MGI PHARMA, Inc.
Address: 5775 West Old Shakopee Road, Suite 100
Bloomington, MN. 55437-3107
Main Telephone
Number: 952/346-4700
Internet Home
Page Address
(URL) www.mgipharma.com
Chief Executive
Officer: Charles N. Blitzer
Chief Financial
Officer: William C. Brown
Investor Relations
Contact: Maggie Knack
Business number: 952/346-4771
E-mail address: mknack@mgipharma.com
Public Relations
Contact: Paul Lehman
Business number: 952/406-3185
E-mail address: plehman@mgipharma.com
Industry: Pharmaceutical
Trading Symbol/
Exchange: MOGN
Market Makers: Piper Jaffray Companies, Inc., Herzog, Heine,
Geduld, Inc., Archipelago, L.L.C., Dain Rauscher Inc., Sherwood
Securities Corp., Knight Securities L.P., Instinet Corporation, Spear,
Leeds & Kellogg
Company description: MGI MGI Mouse Genome Informatics MGI Modular Gateway Interface MGI McKinsey Global Institute MGI Military Geographic Information MGI Marine Geological Institute MGI Policy on the Management of Government Information (Canada) PHARMA, Inc. is an oncology-focused pharmaceutical company that acquires, develops and commercializes proprietary products that address unmet cancer patient needs. MGI is building a balanced product portfolio of proprietary pharmaceuticals, and intends to become a leader in oncology. The Company's growing portfolio includes both revenue-generating marketed products as well as late-stage product candidates. MGI develops its anti-cancer drug candidates with a proven research and development team, markets and promotes its commercial products in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. through its highly experienced 50-person sales organization, and collaborates with other pharmaceutical or biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. in international markets. MGI currently has two compounds in Phase 3 development: irofulven, its promising anti-cancer drug candidate which is currently in a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. in refractory pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. patients, for which it received FDA Fast Track Fast Track is a designation of the Food and Drug Administration that accelerates the approval of experimental drugs, such as experimental cancer treatments, that treat a serious or life-threatening medical condition for which no other drug either exists or works as well. designation in June 2001; and palonosetron, a potent, long-acting 5-HT3 antagonist currently in Phase 3 development for the prevention of chemotherapy-induced nausea and vomiting Nausea and Vomiting Definition Nausea is the sensation of being about to vomit. Vomiting, or emesis, is the expelling of undigested food through the mouth. . MGI is also developing MG98, a second-generation anti-sense compound that targets an important nuclear enzyme and inhibits tumors, currently in a Phase 2 trial. For an overview MGI PHARMA annual sales figures, stock highs/lows, net operating budget, net income, etc., browse to the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of our Website at http://www.mgipharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion